TY - JOUR A1 - Cantoreggi, S. A1 - Lutz, Werner K. T1 - Covalent binding of styrene to DNA in rat and mouse N2 - No abstract available KW - Toxikologie Y1 - 1993 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-60693 ER - TY - JOUR A1 - Gunz, D. A1 - Shephard, S. E. A1 - Lutz, Werner K. T1 - Can nongenotoxic carcinogens be detected with the lacI transgenic mouse mutation assay? N2 - No abstract available KW - Toxikologie Y1 - 1993 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-60707 ER - TY - JOUR A1 - Adami, Hans-Olov A1 - Dragsted, Lars A1 - Enig, Bent A1 - Hansen, Jens A1 - Haraldsdóttir, Jóhanna A1 - Hill, Michael J. A1 - Holm, Lars Erik A1 - Knudsen, Ib A1 - Larsen, Jens-Jorgen A1 - Lutz, Werner K. A1 - Osler, Merete A1 - Overvad, Kim A1 - Sabroe, Svend A1 - Sanner, Tore A1 - Strube, Michael A1 - Sorensen, Thorkild I. A. A1 - Thorling, Eivind B. T1 - Report from the working group on diet and cancer. N2 - No abstract available. KW - Krebs KW - Ernährung Y1 - 1993 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-71601 ER - TY - JOUR A1 - Lutz, Werner K. A1 - Schlatter, Josef T1 - The relative importance of mutagens and carcinogens in the diet. N2 - Known mutagens and carcinogens in the dict were compiled and the risk of cancer was estimated on the basis of average exposure Ievels in Switzerland and carcinogenic potencies from rodent bioassays. The analysis showed that, except for a1cohol, the sum of all known dietary carcinogens could only explain a few percent of the cancer deaths attributed by epidemiologists to dietary factors. The discrepancy was explained by a "carcinogenicity" of excess macronutrients. This hypothesis was based on an evaluation of dietary restriction experiments in rats and mice, where a dramatic reducing effect on spontaneaus tumour formation was seen. From these experiments, a "carcinogenic potency" was deduced for food in excess (TD50 approximately 16 g/kg per day). Ovemutrition in Switzerland was converted into excess food intake and the cancer risk estimated on the basis ofthe TD50 value. The resulting risk of60,000 cases per one million lives wou1d aJlow to explain by overnutrition almost all "diet-related" cancer deaths in humans. KW - Medizin Y1 - 1993 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-86311 ER - TY - JOUR A1 - Fischer, W. H. A1 - Lutz, Werner K. T1 - Short communication : Mouse skin papilloma formation by chronic dermal application of 7,12-dimethylbenz[a]anthracene is not reduced by diet restriction N2 - No abstract available KW - Toxikologie Y1 - 1994 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-60644 ER - TY - JOUR A1 - Grunicke, H. A1 - Pyerin, W. A1 - Eisenbrand, G. A1 - Havemann, K. A1 - Rabes, H. M. A1 - Molling, K. A1 - Schwab, M. A1 - Lutz, Werner K. A1 - Wahrendorf, J. A1 - Schirrmacher, V. T1 - 7th International Symposium of the Division of Experimental Cancer Research (AEK) of the German Cancer Society : [Meeting report] N2 - No abstract available KW - Toxikologie Y1 - 1994 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-60651 ER - TY - JOUR A1 - Shephard, S. E. A1 - Lutz, Werner K. A1 - Schlatter, C. T1 - The lacI transgenic mouse mutagenicity assay: quantitative evaluation in comparison to tests for carcinogenicity and cytogenetic damage in vivo N2 - The detection Iimit of the lacl transgenic mouse mutagenicity assay lies, in practice, at approximately a 50-100% increase in mutant frequency in treated animals over controls. The sensitivity of this assay in detecting genotoxins can be markedly improved by subchronic rather than acute application of the test compound. The lac/ transgenic mouse mutagenicity assay was compared quantitatively to rodent carcinogenicity tests and to presently used in vivo mutagenicity assays. With the genotoxic carcinogens tested thus far, a rough correlation between mutagenic potency and carcinogenic potency was observed: on average, to obtain a doubling in lacl mutant frequency the mice bad to be treated with a total dose equal to 50 times the TD50 daily dose Ievel. This total dose could be administered eilher at a high dose rate within a few days or, preferably, at a low dose rate over several weeks. This analysis also indicated that a lacl experiment using a 250-day exposure period would give a detection Iimit approximately equal to that of a long-term carcinogenicity study. In comparison to the micronucleus test or the chromosome aberration assay, acute sturlies with the presently available lacl system offered no increase in sensitivity. However, subchronic lacl sturlies (3-4-month exposure) resulted in an increase in sensitivity over the established tests by 1-2 orders of magnitude (shown with 2-acetylaminofluorene, N-nitrosomethylamine, N-nitrosomethylurea and urethane). 1t is concluded that a positive result in the lacl test can be highly predictive of carcinogenicity butthat a negative result does not provide a large margin of safety. KW - Toxikologie KW - Transgenie mice KW - Mutagenicity assay KW - Sensitivity KW - Chromosome aberration KW - Micronucleus test KW - Carcinogenic potency Y1 - 1994 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-60638 ER - TY - JOUR A1 - Vogl, Silvia A1 - Lutz, Roman W. A1 - Schönfelder, Gilbert A1 - Lutz, Werner K. T1 - CYP2C9 genotype vs. metabolic phenotype for individual drug dosing - a correlation analysis using flurbiprofen as probe drug JF - PLoS ONE N2 - Currently, genotyping of patients for polymorphic enzymes responsible for metabolic elimination is considered a possibility to adjust drug dose levels. For a patient to profit from this procedure, the interindividual differences in drug metabolism within one genotype should be smaller than those between different genotypes. We studied a large cohort of healthy young adults (283 subjects), correlating their CYP2C9 genotype to a simple phenotyping metric, using flurbiprofen as probe drug. Genotyping was conducted for CYP2C9*1, *2, *3. The urinary metabolic ratio MR (concentration of CYP2C9-dependent metabolite divided by concentration of flurbiprofen) determined two hours after flurbiprofen (8.75 mg) administration served as phenotyping metric. Linear statistical models correlating genotype and phenotype provided highly significant allele-specific MR estimates of 0.596 for the wild type allele CYP2C9*1, 0.405 for CYP2C9*2 (68 % of wild type), and 0.113 for CYP2C9*3 (19 % of wild type). If these estimates were used for flurbiprofen dose adjustment, taking 100 % for genotype *1/*1, an average reduction to 84 %, 60 %, 68 %, 43 %, and 19% would result for genotype *1/*2, *1/*3, *2/*2, *2/*3, and *3/*3, respectively. Due to the large individual variation within genotypes with coefficients of variation >= 20% and supposing the normal distribution, one in three individuals would be out of the average optimum dose by more than 20 %, one in 20 would be 40% off. Whether this problem also applies to other CYPs and other drugs has to be investigated case by case. Our data for the given example, however, puts the benefit of individual drug dosing to question, if it is exclusively based on genotype. KW - cytochrome P450 2C9 KW - warfarin polymorphisms KW - tolbutamide substrate KW - impact pharmacogenetics KW - 4'-hydroxylation KW - allelic variant KW - liver microsomes Y1 - 2015 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-148783 VL - 10 IS - 3 ER -